715 related articles for article (PubMed ID: 16234977)
21. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.
Hofbauer LC; Gori F; Riggs BL; Lacey DL; Dunstan CR; Spelsberg TC; Khosla S
Endocrinology; 1999 Oct; 140(10):4382-9. PubMed ID: 10499489
[TBL] [Abstract][Full Text] [Related]
22. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
23. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
[TBL] [Abstract][Full Text] [Related]
24. Areca nut extracts modulated expression of alkaline phosphatase and receptor activator of nuclear factor kappaB ligand in osteoblasts.
Ling LJ; Ho FC; Chen YT; Holborow DW; Liu TY; Hung SL
J Clin Periodontol; 2005 Apr; 32(4):353-9. PubMed ID: 15811051
[TBL] [Abstract][Full Text] [Related]
25. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.
Nakashima T; Kobayashi Y; Yamasaki S; Kawakami A; Eguchi K; Sasaki H; Sakai H
Biochem Biophys Res Commun; 2000 Sep; 275(3):768-75. PubMed ID: 10973797
[TBL] [Abstract][Full Text] [Related]
26. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
[TBL] [Abstract][Full Text] [Related]
27. Human osteoblast precursors produce extracellular adenosine, which modulates their secretion of IL-6 and osteoprotegerin.
Evans BA; Elford C; Pexa A; Francis K; Hughes AC; Deussen A; Ham J
J Bone Miner Res; 2006 Feb; 21(2):228-36. PubMed ID: 16418778
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
[TBL] [Abstract][Full Text] [Related]
29. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
30. Leptin effect on RANKL and OPG expression in MC3T3-E1 osteoblasts.
Lamghari M; Tavares L; Camboa N; Barbosa MA
J Cell Biochem; 2006 Aug; 98(5):1123-9. PubMed ID: 16479591
[TBL] [Abstract][Full Text] [Related]
31. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Kaji H; Kanatani M; Sugimoto T; Chihara K
Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
[TBL] [Abstract][Full Text] [Related]
32. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
Kondo H; Guo J; Bringhurst FR
J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
[TBL] [Abstract][Full Text] [Related]
33. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta.
Seidlova-Wuttke D; Hesse O; Jarry H; Christoffel V; Spengler B; Becker T; Wuttke W
Eur J Endocrinol; 2003 Oct; 149(4):351-62. PubMed ID: 14514351
[TBL] [Abstract][Full Text] [Related]
34. Osteoprotegerin and receptor activator of nuclear factor-kappa B ligand modulation by enamel matrix derivative in human alveolar osteoblasts.
Galli C; Macaluso GM; Guizzardi S; Vescovini R; Passeri M; Passeri G
J Periodontol; 2006 Jul; 77(7):1223-8. PubMed ID: 16805686
[TBL] [Abstract][Full Text] [Related]
35. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM
J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
[TBL] [Abstract][Full Text] [Related]
36. Influence of baicalin on the expression of receptor activator of nuclear factor-kappaB ligand in cultured human periodontal ligament cells.
Wang GF; Wu ZF; Wan L; Wang QT; Chen FM
Pharmacology; 2006; 77(2):71-7. PubMed ID: 16636611
[TBL] [Abstract][Full Text] [Related]
37. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
[TBL] [Abstract][Full Text] [Related]
38. Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors.
Gallant MA; Samadfam R; Hackett JA; Antoniou J; Parent JL; de Brum-Fernandes AJ
J Bone Miner Res; 2005 Apr; 20(4):672-81. PubMed ID: 15765187
[TBL] [Abstract][Full Text] [Related]
39. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
40. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
